NF1 and cancer: Consistent with our observation that low NF1-expressing NBs are sensitive to SHP099, Nichols and colleagues demonstrated that a different SHP2 allosteric inhibitor, RMC-4550, disrupts RAS loading and MEK/ERK activatior in several NF1 mutant cancer cells (Nichols et al., 2018).